{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:27:04Z","timestamp":1760866024095},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T00:00:00Z","timestamp":1478908800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s11011-016-9912-0","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T23:07:38Z","timestamp":1478905658000},"page":"1365-1367","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L-ornithine-L-aspartate in the management of HE"],"prefix":"10.1007","volume":"31","author":[{"given":"Gerald","family":"Kircheis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,12]]},"reference":[{"key":"9912_CR1","unstructured":"Abdo-Francis JM, P\u00e9rez-Hern\u00e1ndez JL, Hinojosa-Ruiz A, Hern\u00e1ndez-V\u00e1squez JR (2010) Reduction in hospital stay with the use of L-ornithine-L-aspartate (LOLA) in patients with hepatic encephalopathy. Revista de Gastroenterolog\u00eda de M\u00e9xico 2: 135\u2212141"},{"key":"9912_CR2","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1053\/j.gastro.2009.02.050","volume":"136","author":"SK Acharya","year":"2009","unstructured":"Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK (2009) Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 136:2159\u20132168","journal-title":"Gastroenterology"},{"key":"9912_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12235","author":"MR Alvares-da-Silva","year":"2013","unstructured":"Alvares-da-Silva MR, de Araujo A, Vicenzi JR, et al. (2013) Oral L-ornithine-L-aspartate in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled trial. Hepatol Res. doi: 10.1111\/hepr.12235 [Epub ahead of print]","journal-title":"Hepatol Res"},{"key":"9912_CR4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/jgh.12142","volume":"28","author":"M Bai","year":"2013","unstructured":"Bai M, Yang Z, Qi X, Fan D, Han G (2013) L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 28:783\u2013792","journal-title":"J Gastroenterol Hepatol"},{"key":"9912_CR5","unstructured":"Fleig WE, Kircheis G, Spengler U, Zeuzem ST, G\u00f6rtelmeyer R, The German-Austrian-Swiss Multicenter Study Group (1999) Placebo-controlled, double-blind evaluation of L-ornithine\u2013L-aspartate (LOLA) granules in patients with cirrhosis and subclinical (SHE) or mild overt hepatic encephalopathy (HE). J Hepatol 30 (Suppl. 1):65 (abstract)"},{"key":"9912_CR6","first-page":"131","volume":"25","author":"G Kircheis","year":"1996","unstructured":"Kircheis G, Metz M, Frey S, Seiller E (1996) Correlation between pharmacokinetic aspects and clinical efficacy of L-ornithine\u2013L-aspartate (OA): results of randomized, controlled clinical trials. J Hepatol 25:131 (abstract)","journal-title":"J Hepatol"},{"key":"9912_CR7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.510250609","volume":"25","author":"G Kircheis","year":"1997","unstructured":"Kircheis G, Nilius R, Berndt H, et al. (1997) Therapeutic efficacy of L-ornithine-L-aspartate infusion concentrate in patients with liver cirrhosis and hepatic encephalopathy: a placebo-controlled double-blind study. Hepatology 25:1351\u20131360","journal-title":"Hepatology"},{"key":"9912_CR8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1023\/A:1021934607762","volume":"17","author":"G Kircheis","year":"2002","unstructured":"Kircheis G, Wettstein M, vom Dahl S, et al. (2002) Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis 17:453\u2013463","journal-title":"Metab Brain Dis"},{"key":"9912_CR9","first-page":"1052","volume":"67","author":"H Leonhardt","year":"1972","unstructured":"Leonhardt H, Bungert HJ (1972) Therapie der schweren Hyperammoni\u00e4mie. Med Klin 67:1052\u20131056","journal-title":"Med Klin"},{"key":"9912_CR10","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e31828726e1","volume":"80","author":"MJ McPhail","year":"2013","unstructured":"McPhail MJ, Leech R, Grover VP, Fitzpatrick JA, Dhanjal NS, Crossey MM, Pflugrad H, Saxby BK, Wesnes K, Dresner MA, Waldman AD, Thomas HC, Taylor-Robinson SD (2013) Modulation of neural activation following treatment of hepatic encephalopathy. Neurology 80:1041\u20131047","journal-title":"Neurology"},{"issue":"Suppl. 2","key":"9912_CR11","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S1665-2681(19)31610-2","volume":"10","author":"JL P\u00e9rez Hern\u00e1ndez","year":"2011","unstructured":"P\u00e9rez Hern\u00e1ndez JL (2011) Critical analysis of studies evaluating the efficacy of infusion of Lornithine- L-aspartate in clinical hepatic encephalopathy in patients with liver failure. Ann Hepatol 10(Suppl. 2):S66\u2013S69","journal-title":"Ann Hepatol"},{"issue":"Suppl.1","key":"9912_CR12","first-page":"65","volume":"30","author":"N Reynolds","year":"1999","unstructured":"Reynolds N, Downie S, Smith K, Kircheis G, Rennie MJ (1999) Treatment with L-ornithine\u2013L-aspartate infusion restores muscle protein synthesis responsiveness to feeding in patients with cirrhosis. J Hepatol 30(Suppl.1):65 (abstract)","journal-title":"J Hepatol"},{"key":"9912_CR13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/hep.510300311","volume":"30","author":"C Rose","year":"1999","unstructured":"Rose C, Michalak A, Rama Rao KV, Quack G, Kircheis G, Butterworth RF (1999) L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 30:636\u2013640","journal-title":"Hepatology"},{"key":"9912_CR14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0168-8278(05)80553-7","volume":"19","author":"U Staedt","year":"1993","unstructured":"Staedt U, Leweling H, Gladisch R, Kortsik C, Hagm\u00fcller E, Holm E (1993) Effects of ornithine aspartate on plasma ammmonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 19:424\u2013430","journal-title":"J Hepatol"},{"key":"9912_CR15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0168-8278(98)80237-7","volume":"28","author":"S Stauch","year":"1998","unstructured":"Stauch S, Kircheis G, Adler G, et al. (1998) Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 28:856\u2013864","journal-title":"J Hepatol"},{"key":"9912_CR16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gut.31.6.702","volume":"31","author":"K Tarao","year":"1990","unstructured":"Tarao K, Ikeda T, Hayashi K, Sakurai A, Okada T, Ito T, Karube H, Nomoto T, Mizuno T, Shindo K (1990) Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 31:702\u2013706","journal-title":"Gut"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-016-9912-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-016-9912-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-016-9912-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T10:25:12Z","timestamp":1568543112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-016-9912-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,12]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["9912"],"URL":"https:\/\/doi.org\/10.1007\/s11011-016-9912-0","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,12]]}}}